Kawahara Takashi, Miyoshi Yasuhide, Yao Masahiro, Uemura Hiroji
Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Case Rep Oncol. 2019 Aug 6;12(2):589-594. doi: 10.1159/000502054. eCollection 2019 May-Aug.
Dysgeusia is an adverse effect caused by enzalutamide said to affect 1-5% of patients. The reported management strategies include a temporary drug holiday, the prescription of herbal medicine, and changing the timing of enzalutamide intake from morning to before sleep at night. Case 1: A 72-year-old man developed castration-resistant prostate cancer (CRPC) and was administered enzalutamide. After six weeks of enzalutamide installation, he showed taste alternation, and consequently his dysgeusia increased to grade 2; we therefore changed the medicine intake time from morning to night just before sleep without dose reduction. Four weeks after changing the timing, his dysgeusia had improved. Case 2: A 63-year-old man had developed bone metastatic CRPC, so the combination of Ra-223 and enzalutamide (160 mg/body) was introduced. His serum PSA level had gradually decreased, but dysgeusia appeared, so we changed the timing of enzalutamide intake from morning to night just before sleep without dose reduction. One month after changing the timing, his dysgeusia had improved. We herein report two cases of enzalutamide-induced dysgeusia successfully treated by changing the timing of drug intake from morning intake to just before sleep.
味觉障碍是恩杂鲁胺引起的一种不良反应，据说会影响1%至5%的患者。报告的管理策略包括暂时停药、开草药处方以及将恩杂鲁胺的服用时间从早上改为晚上睡前。病例1：一名72岁男性患去势抵抗性前列腺癌（CRPC），接受了恩杂鲁胺治疗。服用恩杂鲁胺六周后，他出现了味觉改变，味觉障碍因此加重至2级；因此，我们在不减量的情况下将服药时间从早上改为晚上睡前。改变时间四周后，他的味觉障碍有所改善。病例2：一名63岁男性患骨转移性CRPC，因此采用了镭-223与恩杂鲁胺（160毫克/人）联合治疗。他的血清前列腺特异抗原（PSA）水平逐渐下降，但出现了味觉障碍，因此我们在不减量的情况下将恩杂鲁胺的服用时间从早上改为晚上睡前。改变时间一个月后，他的味觉障碍有所改善。我们在此报告两例通过将服药时间从早上改为睡前成功治疗的恩杂鲁胺引起的味觉障碍病例。
